Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Gland Pharma Ltd (GLAND) is currently trading at 1,709.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Gland Pharma Limited is a prominent player in the global generic injectables market, operating under a B2B model with essential services like contract development and manufacturing across various systems. The company achieved broad-based revenue growth of 22% YoY in Q3 FY26, reaching INR 16,954 million, driven by both its expansion and integration of Cenexi in France. Gland Pharma is actively expanding cartridge fill and finish capacities from 40 million to 140 million units, signifying growth potential in its complex product pipeline. The acquisition of Cenexi increased Gland Pharma's footprint in Europe and enhanced its manufacturing capabilities, leading to a diversified revenue stream. Strategic initiatives, including partnerships and CDMO contracts, position Gland Pharma for sustained growth, focusing on high-value, differentiated products.
Over the past 52 weeks, Gland Pharma Ltd has traded between a low of ₹1,200.00 and a high of ₹2,130.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Gland Pharma Ltd has a market capitalization of approximately 29,575.42. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Gland Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 33.25 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 29,575.42 Cr, Gland Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Gland Pharma Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Gland Pharma Ltd is 33.25. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The most significant announcement is the 'Biopharma Shakti' scheme, which allocates ₹10,000 crore over five years to make India a global hub for manufacturing biologics and biosimilars, directly aligning with Gland Pharma's strategic focus.
The share price jumped over 9% due to strong Q3 FY26 financial results, which included a 37% year-on-year increase in net profit and a 22% rise in revenue.
Gland Pharma reported a 27.7% year-on-year increase in consolidated net profit to ₹261 crore. Revenue from operations grew by 22.5% to ₹1,695 crore for the quarter ended December 31, 2025.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2970.00 | 37,040 Cr | 36.60 | 8.58 | 0.95 | 22.56 | 27.85 | 17.89 | |
1790.30 | 29,575 Cr | 34.82 | 3.09 | 1.00 | 8.27 | 12.46 | 7.18 | |
996.85 | 21,089 Cr | 64.06 | 9.29 | 0.00 | 12.62 | 16.34 | 9.99 | |
1369.00 | 18,886 Cr | 43.26 | 5.37 | 0.53 | 13.45 | 14.38 | 6.57 | |
1686.70 | 12,732 Cr | 20.96 | 4.03 | 0.36 | 18.64 | 23.29 | 17.76 | |
770.25 | 12,671 Cr | 88.74 | 11.04 | 0.00 | 26.49 | 22.49 | 11.57 | |
172.80 | 7,769 Cr | 21.71 | 2.89 | 0.47 | 13.08 | 16.13 | 10.51 |
Press Release
Gland Pharma received USFDA tentative approval for its ANDA for Brimonidine Tartrate Ophthalmic Solution 0.025% (OTC), bioequivalent to Lumify; the product had ~USD 39m US sales for the 12 months to Sep 2025 (IQVIA).
Change in Key Management Personnel
Gland Pharma’s CEO Mr. Shyamakant Giri submitted his resignation (letter dated Feb 24, 2026), which the Board accepted on Mar 3, 2026; he will cease as CEO and KMP effective close of business on Apr 30, 2026.
Change in Key Management Personnel
Gland Pharma announced CEO Mr. Shyamakant Giri resigned (resignation letter dated Feb 24, 2026); the Board accepted it on Mar 3, 2026 and he will cease as CEO and KMP effective close of business on Apr 30, 2026.
Bearish
2
Neutral
3
Bullish
9
Bearish
34
Neutral
3
Bullish
9
Bearish
32
Neutral
0
Bullish
0
Gland Pharma Limited is a prominent player in the global generic injectables market, operating under a B2B model with essential services like contract development and manufacturing across various systems.
The company achieved broad-based revenue growth of 22% YoY in Q3 FY26, reaching INR 16,954 million, driven by both its expansion and integration of Cenexi in France.
Gland Pharma is actively expanding cartridge fill and finish capacities from 40 million to 140 million units, signifying growth potential in its complex product pipeline.
The acquisition of Cenexi increased Gland Pharma's footprint in Europe and enhanced its manufacturing capabilities, leading to a diversified revenue stream.
Strategic initiatives, including partnerships and CDMO contracts, position Gland Pharma for sustained growth, focusing on high-value, differentiated products.
Pharmaceuticals
Pharmaceuticals - Indian - Formulations
29,575 Cr
Low Risk
33.2
44.0
1.6
3.1
2,130.00
1,200.00
Sales CAGR
Profit CAGR
ROE
ROCE
